Breast Cancer Pathways
Development of Predictive Biomarkers for the Accurate Identification of Responders to Breast Cancer
An important goal of personalized medicine in cancer is to identify patients who will respond to appropriate therapies. In order to achieve this goal biomarkers are required to predict potential responders vs. non-responders with high sensitivity and specificity. Applied Informatic Solutions (www.AppliedInformaticSolutions.com) has developed a gene expression biomarker for breast cancer patients that can predict whether patients will respond to paclitaxel and chemotherapy with a sensitivity of 90%, and specificity of 92%. Importantly, this test can predict with a very high accuracy if a breast cancer patient will be free of invasive cancer following the completion of the standard chemotherapeutic treatment, and could be used by physicians to minimize both the extent of the surgery and its consequences. This gene expression biomarker is applicable regardless of the estrogen receptor, progesterone receptor, and HER2 status of the patient. Confirmation of the clinical utility of this biomarker will allow breast cancer patients and their oncologists to select the proper course of treatment with greater confidence.
Nov 16, 2011